<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593553</url>
  </required_header>
  <id_info>
    <org_study_id>Strokestop</org_study_id>
    <nct_id>NCT01593553</nct_id>
  </id_info>
  <brief_title>Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden</brief_title>
  <official_title>Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether screening for atrial fibrillation by
      intermittent ECG recording and initiation of anticoagulation treatment among high risk
      individuals is cost-effective and can lower the incidence of stroke.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ischaemic or haemorrhagic stroke, systemic embolism, major bleeding leading to hospitalization or death from any cause</measure>
    <time_frame>Five years. Interim analysis after 3 years.</time_frame>
    <description>A composite endpoint of incidence of ischamemic and haemorrhagic stroke, incidence of systemic embolism, major bleeding requiring hospitalization and all cause mortality in the group randomized to screening compared to the control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischaemic stroke</measure>
    <time_frame>Five years. Interim analysis after 3 years.</time_frame>
    <description>Incidence of ischaemic stroke in the group randomized to screening compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischaemic stroke and systemic thromboembolism</measure>
    <time_frame>Five years. Interim analysis after 3 years.</time_frame>
    <description>Incidence of ischaemic stroke and systemic thromboembolism in the group randomized to screening compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischaemic stroke and systemic thromboembolism</measure>
    <time_frame>Five years. Interim analysis after 3 years.</time_frame>
    <description>Incidence of ischaemic stroke and systemic thromboembolism in the group participating in screening (as treated) compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dementia</measure>
    <time_frame>Five years. Interim analysis after 3 years.</time_frame>
    <description>Incidence of dementia in the group randomized to screening compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>Five years. Interim analysis after 3 years.</time_frame>
    <description>All cause mortality in the group randomized to screening compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Five years. Interim analysis after 3 years.</time_frame>
    <description>Cardiovascular in the group randomized to screening compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to cardiovascular disease</measure>
    <time_frame>Five years. Interim analysis after 3 years.</time_frame>
    <description>Hospitalization due to cardiovascular disease in the group randomized to screening compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischaemic or haemorrhagic stroke, systemic embolism, major bleeding leading to hospitalization, hospitalization due to cardiovascular disease or death from any cause</measure>
    <time_frame>Five years. Interim analysis after 3 years.</time_frame>
    <description>In the group randomized to screening compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectivity</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation and compliance to oral anticoagulation therapy</measure>
    <time_frame>Five years</time_frame>
    <description>The National Prescription Drug's register will be used to study intiation and duration of oral anticoagulation therapy in a as-treated and per-protocol analysis in the screened population compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of atrial fibrillation</measure>
    <time_frame>Five years</time_frame>
    <description>Incidence of atrial fibrillation in the group randomized to screening compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary embolism and deep vein thrombosis</measure>
    <time_frame>Five years</time_frame>
    <description>Incidence of pulmonary embolism and deep vein thrombosis in the group randomized to screening compared to the control group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7173</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>ECG screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily screening using intermittent ECG recorder (Zenicor) for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ECG screening for atrial fibrillation using intermittent ECG recorder</intervention_name>
    <description>ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.</description>
    <arm_group_label>ECG screening</arm_group_label>
    <other_name>Zenicor ECG recorder</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 75-76 years of age living in the region of Stockholm or Halland

        Exclusion Criteria:

          -  Not fulfilling the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska Trial Alliance, KTA Prim</name>
      <address>
        <city>Stockholm</city>
        <zip>11361</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Professor MÃ¥rten Rosenqvist</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Screening</keyword>
  <keyword>Stroke prevention</keyword>
  <keyword>Cost effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

